FREE TRACKED SHIPPING ON ORDERS OVER $299 $150

Semaglutide – 10mg

$99.99

Out of stock

PRODUCT AVAILABILITY

Get notified when it’s in stock

Join this product’s notification list and we’ll email you when it becomes available. No payment or backorder is created.

Product notifications are separate from marketing. Your address is used for this availability request unless you also select site updates.
SKU: SEMA-10MG Categories: ,
  • Research focus: GLP-1 receptor signalling and metabolic-pathway research
  • Compound class: Long-acting glucagon-like peptide-1 analogue
  • Researchers are exploring: Appetite cues, blood-sugar regulation and nutrient-response signalling
Fast Order ProcessingIn-stock orders prepared promptly
Tracking ProvidedEmailed when your order is on its way
Canadian SupportHelp when you need it

RESEARCH AT A GLANCE

A clearer view of the research landscape

01

Primary pathway

GLP-1 receptor signalling

02

Researchers explore

glucose-responsive signalling, appetite pathways and energy balance

03

Research coverage

Extensive clinical and translational research

Semaglutide — 10mg

Product Overview

Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone involved in nutrient-responsive signalling. Its structure was engineered to increase stability and albumin association while retaining activity at the GLP-1 receptor.

Research Background

GLP-1 receptor activation is studied in relation to cyclic-AMP signalling, glucose-dependent endocrine responses, gastrointestinal signalling and communication between peripheral tissues and the central nervous system. Semaglutide is therefore used as a reference compound in receptor pharmacology, metabolic signalling and peptide-engineering research.

Current Areas of Investigation

Published work includes receptor-binding and signalling assays, cellular models, animal studies and regulated clinical research. Laboratory investigations may examine receptor activation, desensitization, internalization, downstream second-messenger responses and the consequences of extended peptide exposure.

In Plain Language

Researchers use semaglutide to better understand how GLP-1 signalling affects appetite cues, blood-sugar regulation, digestion and the way biological systems respond to nutrients. Studies have found that activating this pathway can slow digestive signalling, increase feelings of fullness and influence glucose-dependent insulin and glucagon responses.

In practical terms, the research is exploring how one receptor pathway can affect several connected areas at once: hunger signalling, food intake, glucose control and longer-term metabolic regulation. These effects are well documented in regulated research, although the size and nature of the response depends on the model, dose and study conditions.

Product Specifications

  • Catalogue No.: SEMA10
  • Vial Size: 10mg

Quality & Documentation

Lot-specific product documentation and Certificate of Analysis (COA) information may be available through AURAPEP where applicable.

Research Use Only

RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION. Supplied strictly for laboratory, analytical and research purposes. Not intended for self-administration or to diagnose, treat, cure or prevent any disease.

AURAPEP RESEARCH LIBRARY

Related Research

Explore the scientific background, evidence and limitations associated with this research compound.

Explore the complete Research Library

PRODUCT FAQ

Three common research questions

Explore concise, product-specific answers without leaving this page.

PRODUCT FAQ

Semaglutide – 10mg

01

What is Semaglutide and which pathway do researchers study?

Semaglutide is studied in relation to gLP-1 receptor signalling. Researchers use it to investigate glucose-responsive signalling, appetite pathways and energy balance.

02

What are researchers investigating?

The current research landscape includes Extensive clinical and translational research. Study designs may involve biochemical assays, cell systems, animal models or regulated human research depending on the compound, and results should be interpreted within the limits of each model.

03

How does it differ from related research compounds?

Semaglutide primarily targets the GLP-1 receptor. Tirzepatide is studied through GIP and GLP-1 receptors, while retatrutide adds glucagon-receptor activity, allowing comparison of single-, dual- and triple-receptor signalling.

Research information is provided for scientific context. Product supplied for research use only.